Last updated: April 25, 2026
Which suppliers produce or market paroxetine mesylate?
Paroxetine mesylate is supplied through a mix of branded finished-dose manufacturers and generic finished-dose manufacturers. Public sourcing lists for the finished product name “paroxetine mesylate” typically appear under finished dosage form entries (tablets/capsules) rather than as a single global API vendor list.
The most consistently searchable supplier set for “paroxetine mesylate” is therefore:
- Finished-dose manufacturers that list “paroxetine mesylate” as the active ingredient on product labels and regulatory filings.
- Generic manufacturers that sell “paroxetine mesylate” tablets in specific jurisdictions.
- API producers only where they explicitly sell under “paroxetine mesylate” (many API supply chains trade under the freebase or intermediate salts and use conversion steps for salt formation).
What are the practical supplier categories for sourcing paroxetine mesylate?
1) Finished-dose tablet/capsule suppliers (API-to-finished supply)
These companies market “paroxetine mesylate” in standard oral solid forms (most commonly immediate-release tablets). In sourcing practice, this is the category that reliably maps to buyer procurement.
Typical buyer-facing offerings
- Paroxetine mesylate tablets (strength varies by country)
- Private label packaging options through distributors
2) API suppliers that can support conversion to the mesylate salt
API vendors frequently supply paroxetine base or paroxetine salt forms under technical contracts; salt conversion to mesylate is then handled by:
- the buyer’s formulation site, or
- a dedicated salt-formulation partner.
Buyer-facing distinction
- “API manufacturer” does not always mean “mesylate salt supplier.” Many supply paroxetine base, and salt formation happens downstream.
3) Distributors and tender intermediaries
Where direct manufacturing contracts are not feasible, procurement often routes through:
- region-specific pharmaceutical distributors
- tender procurement channels used by hospitals and wholesalers
Which firms are repeatedly associated with paroxetine mesylate tablets?
Below is a targeted supplier list drawn from widely documented branded and generic product markets. Names are the practical sourcing targets for procurement of finished paroxetine mesylate.
Branded (origin-linked) market suppliers
- GlaxoSmithKline (GSK)
Commonly associated with branded paroxetine products (historically marketed as paroxetine hydrochloride in many jurisdictions; where “mesylate” appears it is tied to local salt-formulation/labeling practices).
Generic finished-dose manufacturers (multi-jurisdiction suppliers)
The market for paroxetine mesylate tablets is served by many global generics manufacturers. The procurement-relevant set typically includes manufacturers in the following countries/regions:
- India
- China
- Turkey
- EU generics platforms
- MENA generics suppliers
A procurement-grade “who supplies paroxetine mesylate” list cannot be completed from the open web without tying each name to a specific regulatory listing (country + dosage form + strength). As written, “suppliers for the pharmaceutical drug PAROXETINE MESYLATE” requires jurisdiction-anchored product listings to avoid misidentifying companies that only supply paroxetine hydrochloride or paroxetine base.
What exact product attributes determine supplier eligibility?
Procurement qualification for “paroxetine mesylate” should be based on the following attributes, which drive whether a supplier truly provides the mesylate salt (not another salt) and whether the supply is fit-for-market:
- Salt form: mesylate (confirm in specification and COA)
- Dosage form: immediate-release tablets or controlled-release forms (if any)
- Strength: country-dependent strength (varies by market)
- Regulatory status: approved listing in the buyer’s market (e.g., EMA/National agency)
- GxP status: GMP manufacturing and batch traceability
- Supply chain: whether supplier ships finished product vs API
How to structure a paroxetine mesylate supplier short list (actionable)
Finished-dose procurement shortlist build
- Confirm each candidate lists paroxetine mesylate (not paroxetine hydrochloride).
- Obtain proof of release testing method for salt form identity (typically HPLC with method-specific salt detection).
- Validate dosage form and strength match to tender/labeling.
API procurement shortlist build
- Confirm supplier specification states paroxetine mesylate or provides paroxetine base with a salt-formation capability contract.
- Require mesylate-grade impurities profile and polymorph control statement where applicable.
- Request salt-form conversion validation plan (if paroxetine base is supplied).
Key Takeaways
- “Paroxetine mesylate” sourcing is most reliably executed through finished-dose tablet suppliers that explicitly list the mesylate salt in product labeling and regulatory filings.
- API vendors may supply paroxetine base; salt conversion to mesylate often happens downstream, so “paroxetine supplier” does not automatically mean “paroxetine mesylate supplier.”
- A defensible supplier list requires jurisdiction and dosage-form confirmation to ensure the supplier actually sells the mesylate salt.
FAQs
1) Is paroxetine mesylate sourced mainly as an API or as finished tablets?
Mostly as finished tablets in routine pharma procurement because market listings and tenders usually specify the salt-form in the dosage form.
2) Do all paroxetine API suppliers also supply paroxetine mesylate?
No. Many sell paroxetine base or another salt, with mesylate formation handled later.
3) What documentation proves a supplier truly provides the mesylate salt?
The specification and batch COA confirming the salt form identity, alongside the regulatory dossier listing for the marketed product.
4) Does the branded origin company supply paroxetine mesylate directly?
Branded legacy suppliers historically dominated paroxetine therapy markets, but local salt forms depend on the jurisdiction and product labeling.
5) How should a buyer avoid getting the wrong salt form?
Match the tender/label to supplier documentation that explicitly states “paroxetine mesylate” for the exact dosage form and strength.
References
[1] U.S. National Library of Medicine. PubChem Compound Summary: Paroxetine. (Accessed 2026-04-25).
[2] EMA. European public assessment reports for paroxetine products (paroxetine salt form determined by product dossier). (Accessed 2026-04-25).
[3] FDA. Drug product information for paroxetine-containing products (salt form determined by label/product listing). (Accessed 2026-04-25).
